RYBELSUS
Drug
Novo Nordisk Inc
Total Payments
$30.3M
Transactions
145,859
Doctors
42,831
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $20.2M | 119,934 | 41,366 |
| 2020 | $10.1M | 25,815 | 4,331 |
| 2019 | $57,093 | 110 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.1M | 37,677 | 46.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12.2M | 6,777 | 40.2% |
| Food and Beverage | $2.8M | 97,753 | 9.3% |
| Travel and Lodging | $727,959 | 3,006 | 2.4% |
| Consulting Fee | $482,965 | 505 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $1,000 | 1 | 0.0% |
| Education | $612.12 | 140 | 0.0% |
Payments by Type
General
$16.2M
108,182 transactions
Research
$14.1M
37,677 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EX9924-4473 | Novo Nordisk AS | $10.1M | 32 |
| NN9924-4635 | Novo Nordisk AS | $2.7M | 2 |
| NN9924-4437 | Novo Nordisk AS | $552,427 | 4 |
| NN6535-4725 | Novo Nordisk AS | $347,572 | 3 |
| NN9924-4669 | Novo Nordisk AS | $117,298 | 0 |
| NN9924-4558 | Novo Nordisk AS | $71,953 | 0 |
| EX9924-4473 | Novo Nordisk Inc | $64,537 | 6 |
| NN9924-4257 | Novo Nordisk AS | $28,883 | 0 |
| NN9924-4309 | Novo Nordisk AS | $21,150 | 13 |
| NN9924-4280 | Novo Nordisk AS | $20,772 | 0 |
| NN9924-4558 | Novo Nordisk Inc | $18,300 | 4 |
| NN9924-4558-001 | Novo Nordisk AS | $15,444 | 0 |
| NN9931-4296 | Novo Nordisk AS | $14,220 | 0 |
| NN9931-4492 | Novo Nordisk AS | $13,650 | 0 |
| NN9924-4338 | Novo Nordisk AS | $10,625 | 16 |
| NN9924-4473 | Novo Nordisk AS | $2,778 | 1 |
| EX9536-4388 | Novo Nordisk AS | $1,275 | 2 |
| NN9924-4473 | Novo Nordisk Inc | $800.00 | 1 |
| NN9924-4221 | Novo Nordisk AS | $600.00 | 0 |
| NN9536-4374 | Novo Nordisk AS | $375.00 | 1 |
Top Doctors Receiving Payments for RYBELSUS — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $61,414 | 56 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rancho Cucamonga, CA | $61,237 | 83 |
| , MD | Endocrinology, Diabetes & Metabolism | Miami, FL | $61,202 | 58 |
| , M.D | Endocrinology, Diabetes & Metabolism | Festus, MO | $61,158 | 59 |
| , MD | Internal Medicine | Aliso Viejo, CA | $60,990 | 71 |
| , NP | Adult Health | Silver Spring, MD | $60,599 | 68 |
| , MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $60,311 | 62 |
| , DO | Endocrinology, Diabetes & Metabolism | Rapid City, SD | $59,807 | 58 |
| , M.D | Internal Medicine | San Ramon, CA | $59,036 | 81 |
| , M.D | Family Medicine | Manhattan, KS | $58,445 | 66 |
| , M.D | Internal Medicine | Mesquite, TX | $58,359 | 69 |
| , M.D | Endocrinology, Diabetes & Metabolism | Leander, TX | $57,923 | 62 |
| , M.D | Endocrinology, Diabetes & Metabolism | Jacksonville, FL | $57,893 | 60 |
| , M.D | Endocrinology, Diabetes & Metabolism | Jackson, MS | $57,507 | 55 |
| , MD | Internal Medicine | Nashville, TN | $56,599 | 57 |
| , M.D | Endocrinology, Diabetes & Metabolism | Lawrenceville, GA | $56,496 | 53 |
| , DO | Endocrinology, Diabetes & Metabolism | Henderson, NV | $55,229 | 59 |
| , MD | Endocrinology, Diabetes & Metabolism | Sterling, VA | $54,944 | 54 |
| , M.D | Endocrinology, Diabetes & Metabolism | Downey, CA | $54,542 | 71 |
| , MD | Endocrinology, Diabetes & Metabolism | Farmington Hills, MI | $53,643 | 47 |
| , M.D | Endocrinology, Diabetes & Metabolism | Kihei, HI | $53,366 | 108 |
| , MD, FACE | Endocrinology, Diabetes & Metabolism | Columbus, OH | $52,953 | 45 |
| , MD | Endocrinology, Diabetes & Metabolism | Santa Barbara, CA | $52,788 | 56 |
| , PA-C | Medical | Albany, NY | $52,743 | 70 |
| , M.D | Internal Medicine | Bayside, NY | $52,532 | 66 |
Ad
Manufacturing Companies
- Novo Nordisk Inc $16.3M
- Novo Nordisk AS $14.0M
Product Information
- Type Drug
- Total Payments $30.3M
- Total Doctors 42,831
- Transactions 145,859
About RYBELSUS
RYBELSUS is a drug associated with $30.3M in payments to 42,831 healthcare providers, recorded across 145,859 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk Inc.
Payment data is available from 2019 to 2021. In 2021, $20.2M was paid across 119,934 transactions to 41,366 doctors.
The most common payment nature for RYBELSUS is "Unspecified" ($14.1M, 46.5% of total).
RYBELSUS is associated with 20 research studies, including "EX9924-4473" ($10.1M).